CONTACT | Print Page | Sign In | Join
Business Wire Life Sciences News (US)
Share |

Global Implantable Drug Delivery Devices Market to surpass US$ 21,778.8 Million by 2027, Says Coherent Market Insights (CMI)Open in a New Window

SEATTLE--(BUSINESS WIRE)-- #ContraceptiveDrugDeliveryDevices--North America region is expected to hold a dominant position in the global implantable drug delivery devices market over the forecast 2020-2027.

 

Jasper Therapeutics Doses First Patient in Phase 1 Clinical Trial of JSP191 as Conditioning Agent for Patients with Myelodysplastic Syndromes/Acute Myeloid Leukemia Undergoing Hematopoietic Cell TransplantationOpen in a New Window

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, today announced that the first patient has been dosed in a multicenter Phase 1 clinical trial of JSP191, a first-in-class humanized monoclonal antibody. The trial is evaluating JSP191 as a conditioning agent in patients with two types of hematologic disorders – myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) – who are undergoing blood or

 

Pfizer Invites Public to View and Listen to Webcast of October 27 Conference Call with AnalystsOpen in a New Window

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 27, 2020. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2020 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Info

 

Thomas H. Lee Partners and Frazier Healthcare Partners Acquire AdareOpen in a New Window

BOSTON & SEATTLE--(BUSINESS WIRE)--Thomas H. Lee Partners, L.P. (“THL”) and Frazier Healthcare Partners (“Frazier”) today announced they have acquired Adare Pharmaceuticals, which will be rebranded Adare Pharma Solutions (“Adare”), a leading specialty contract development and manufacturing organization (CDMO) and global provider of advanced pharmaceutical technologies, from TPG Capital. The acquisition includes Adare’s CDMO, pharmaceutical technology and microbiome businesses, while TPG Capital

 

TPG Forms Ellodi Pharmaceuticals to Continue Clinical Development of APT-1011 for Treatment of Eosinophilic EsophagitisOpen in a New Window

SAN FRANCISCO & FORT WORTH, Texas--(BUSINESS WIRE)--TPG Capital, the private equity platform of alternative asset firm TPG, announced today that it has formed a new specialty pharmaceutical company called Ellodi Pharmaceuticals. Ellodi Pharmaceuticals is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare). The formation of Ellodi Pharmaceuticals follows TPG Capital

 

Reemo Health Receives Provider Approval, Giving More Users Access to Personal Independence SmartwatchOpen in a New Window

MINNEAPOLIS--(BUSINESS WIRE)--Reemo Health Receives Provider Approval, Giving More Users Access to Personal Independence Smartwatch.

 

Global Mucopolysaccharidosis (MPS) Treatment Market to Surpass US$ 3,014.9 Million by 2027, Says Coherent Market Insights (CMI)Open in a New Window

SEATTLE--(BUSINESS WIRE)-- #EnzymeReplacementTherapy--North America is expected to hold a dominant position in the global mucopolysaccharidosis (MPS) treatment market over the forecast 2020-2027.

 

Yale Gynecologist Mary Jane Minkin, MD Shares Advice on Sexuality, Intimacy & Arousal Following a Breast Cancer DiagnosisOpen in a New Window

NEW HAVEN, Conn.--(BUSINESS WIRE)--Yale OB/GYN Mary Jane Minkin, shares insights on the emotional and physical impacts of a breast cancer diagnosis on sexuality and intimacy.

 

Marinus Announces One-for-Four Reverse Stock SplitOpen in a New Window

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS--Marinus Pharmaceuticals announced that it will effect a one-for-four reverse stock split of its common stock at 5:00 pm ET today.

 

Medigate Enters into Agreement with Arrow Electronics to Bring IoT Device Security to Healthcare InstitutionsOpen in a New Window

NEW YORK--(BUSINESS WIRE)-- #IoT--Medigate, the leader in IoT and medical device security and asset management, today announced that it has entered into an agreement with Arrow Electronics, Inc. to bring healthcare delivery organizations (HDOs) award-winning cybersecurity solutions for their connected devices. The agreement will help HDOs in securing the right powerful cybersecurity threat protection solution for their clinical networks. “The healthcare industry is under attack, with the frequency of

 

Cerebras Systems Expands Global Footprint with New Offices in Tokyo, Japan, and Toronto, CanadaOpen in a New Window

LOS ALTOS, Calif.--(BUSINESS WIRE)-- #AI--Cerebras Systems Expands Global Footprint with New Offices in Tokyo, Japan, and Toronto, Canada

 

Genosity Announces Strategic Software Collaboration with PGDx to Support Distribution of PGDx elio™ Tissue Complete to LaboratoriesOpen in a New Window

NEW YORK--(BUSINESS WIRE)--Genosity, Inc., an innovative biotechnology company that provides comprehensive software and technical solutions to enable precision medicine announced today that it has entered into a strategic collaboration with Personal Genome Diagnostics Inc. (PGDx), one of the leading companies in cancer genomics, that recently received market clearance from the U.S. Food and Drug Administration (FDA) for PGDx elio™ tissue complete, a comprehensive diagnostic kit for genomic prof

 

Aphena Pharma Announces Massive Expansion in TennesseeOpen in a New Window

COOKEVILLE, Tenn.--(BUSINESS WIRE)-- #contractpharma--Aphena begins game-changing $21 million expansion, including capacity for biologics and cold chain storage, of its Solid Dose Division in Tennessee.

 

Illinois HIV Care Connect Encourages Social Media Conversations in “Speaking Up About HIV Stigma” CampaignOpen in a New Window

SPRINGFIELD, Ill.--(BUSINESS WIRE)-- #ADAP--Illinois HIV Care Connect Encourages Social Media Conversations in “Speaking Up About HIV Stigma” Campaign.

 

Promega Developing OncoMate™ MSI Assay as Companion Diagnostic for Endometrial Cancer Drug Candidate from IncyteOpen in a New Window

MADISON, Wis.--(BUSINESS WIRE)--Promega will develop its OncoMate™ MSI Assay as a companion diagnostic test for Incyte’s anti-PD-1 drug candidate in endometrial cancer.

 

Aural Analytics, Inc. Announces the Launch of A2E, A Software Development Kit for Clinical-Grade Speech Collection and AnalyticsOpen in a New Window

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Aural Analytics, Inc., an industry leading speech neuroscience and speech analytics technology company, announced today it has launched A2ETM, a mobile application SDK and Web API designed to make speech collection and cloud-based analytics ubiquitous across clinical research, in any health application, and for in-clinic and remote settings. As the healthcare community continues to recognize the power of speech analysis for use in the identification and track

 

PURPLESUN FMUV: Weapon of Defense Battling An Invisible Enemy COVID-19Open in a New Window

NEW YORK--(BUSINESS WIRE)--PURPLESUN form a private sector partnership to provide FMUV Shadowless Deliver light decontamination technology to Government Agencies.

 

FDA Sued for Ignoring Petition Calling for Breast Cancer Warning Labels on CheeseOpen in a New Window

WASHINGTON--(BUSINESS WIRE)--The Physicians Committee for Responsible Medicine filed a lawsuit on Sept. 22 against the Food and Drug Administration (FDA) for failing to respond to a petition that asks the agency to require cheese manufacturers to add the following warning label on all dairy cheese products: “Dairy cheese contains reproductive hormones that may increase breast cancer mortality risk.” The petition, which was filed on Oct. 3, 2019, cites several studies linking consumption of chee

 

PreCheck Partners With KEO World to Provide Medical Equipment Financing for Its PC8B Medical Device for Sale in the United StatesOpen in a New Window

MIAMI--(BUSINESS WIRE)--PreCheck partners with KEO World to provide medical equipment financing for its PC8B medical device

 

Dexcom G6 Continuous Glucose Monitoring System Now Available at Veterans Affairs Pharmacies Across the United StatesOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Dexcom G6 Continuous Glucose Monitoring System Now Available at Veterans Affairs Pharmacies Across the United States

 

Sunovion Answers Is Named a J.D. Power 2020 Certified Customer Service ProgramSMOpen in a New Window

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Answers Is Named a J.D. Power 2020 Certified Customer Service Program

 

Simulations Plus Partners with Large Pharmaceutical Company to Validate AI-Driven Drug Design Capabilities in ADMET Predictor®Open in a New Window

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced that it has partnered with a large pharmaceutical company to validate the AIDD Module in ADMET Predictor 10.0 (APX).

 

Genetics Research and Oxford Nanopore Technologies Sign Non-Exclusive Licensing Agreement for Genetics Research’s Patented DNA Negative Enrichment Technology PlatformOpen in a New Window

WALTHAM, Mass.--(BUSINESS WIRE)--Genetics Research non-exclusively licenses proprietary targeted DNA enrichment technologies to Oxford Nanopore Technologies.

 

Eikonoklastes Therapeutics Appoints Tom Finn, Retired President P&G Global Personal Health Care, to Board of DirectorsOpen in a New Window

CINCINNATI--(BUSINESS WIRE)--Eikonoklastes Therapeutics names Tom Finn, retired president, P&G Global Personal Health Care, former president, P&G Pharmaceuticals, to its Board.

 

ONETRAC LXD and ONETRAC LXS Join obp’s Family of Single-Use Illuminating Surgical DevicesOpen in a New Window

LAWRENCE, Mass.--(BUSINESS WIRE)--obp, the leading global developer of single-use, self-contained, illuminating medical devices, today announced the launch of ONETRAC LXD, a single-use, cordless dual-blade surgical retractor with integrated multi-LED light source and dual smoke evacuation channels and ONETRAC LXS, a single-use suction device with integrated, cordless radial LED light source. ONETRAC LXD’s innovative patent-pending dual-blade LED circuitry enables instantaneous transition betwee

 

ViewSonic Introduces Health Flex Hand-Sanitizing Stations with Integrated Display and Media Player OptionsOpen in a New Window

BREA, Calif.--(BUSINESS WIRE)-- #HealthKiosk--ViewSonic Introduces Health Flex Hand-Sanitizing Stations with Integrated Display and Media Player Options

 

Ohana Biosciences Completes Enrollment in the SPRING Clinical Trial for Spertility, a Novel Sperm Cell Treatment to Improve Outcomes in Assisted Reproductive TechnologyOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ohana Biosciences, a pioneering reproductive health company that created the world’s first sperm biology platform for sperm-based products, today announced it has completed patient enrollment in its SPRING study (SPeRtility, IVF Next Generation) of Spertility™. Spertility is a sperm cell treatment designed to improve outcomes for people using Assisted Reproductive Technology (ART), such as In-Vitro Fertilization (IVF). “Completing enrollment in our initial cli

 

Axial Biotherapeutics Appoints Federico Bolognani, M.D., Ph.D., Vice President and Head of Clinical ScienceOpen in a New Window

WALTHAM, Mass.--(BUSINESS WIRE)-- #autism--Axial Biotherapeutics Appoints Federico Bolognani, M.D., Ph.D., Vice President and Head of Clinical Science

 

LinkedIn Unveils 2020 U.S. Top Startups ListOpen in a New Window

SUNNYVALE, Calif.--(BUSINESS WIRE)-- #LinkedInTopStartups--LinkedIn releases its annual Top Startups list, ranking the top 50 emerging and growing startups in the U.S.

 

Waters Establishes Flagship Innovation and Research Laboratory in Cambridge, MAOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) announced this week at Biotech Week Boston the establishment of Immerse™ Cambridge, a new Waters' research laboratory in the heart of Cambridge’s Kendall Square. Immerse Cambridge will serve as a strategic, collaborative space in the community, where Waters can partner with academia, research and industry to accelerate the next generation of scientific advancements. “Immerse Cambridge will house the latest analytical instruments a

 

TransMed7, LLC Announces First Results From Clinical Use of its Vacuum-Assisted, Single Insertion - Multiple Collection (SIMC™) Platform of Breast Biopsy DevicesOpen in a New Window

PHOENIX--(BUSINESS WIRE)--TransMed7, LLC announced today that the first of the vacuum-assisted, Single Insertion - Multiple Collection (SIMC™) breast biopsy procedures utilizing its SpeedBird 38 soft tissue biopsy device was successfully performed by Dr. Richard Fine, a distinguished surgeon and former Chairman and President of the American Society of Breast Surgeons (ASBrS). TransMed7 anticipates participating in the next ASBrS meeting to be held in Orlando, Florida, where it will report the c

 

Sinovac Commences Phase III Clinical Trials for COVID-19 Vaccine Candidate in TurkeyOpen in a New Window

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that it has recently commenced phase III clinical trials for its inactivated COVID-19 vaccine candidate developed by Sinovac Life Sciences (Sinovac LS), or “CoronaVac,” in Turkey. The phase III clinical trial seeks to test efficacy and safety of CoronaVac in Turkey and aims to be a pivotal study to support the licensure of this pro

 

Second Sight Medical Products Inc. Announces Resumption of Its Early Feasibility Study of the Orion® Cortical Visual Prosthesis at UCLAOpen in a New Window

LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the resumption of its Early Feasibility Study of the Orion® Visual Cortical Prosthesis System (“Orion”) at UCLA Medical Center (“UCLA”). The study, which includes four participants at UCLA and two participants at Baylor College of Medicine (“

 

Soleo Health’s Monique Nelson Wins Gold Stevie® Award in the 2020 International Business Awards®Open in a New Window

FRISCO, Texas--(BUSINESS WIRE)-- #SOLEOHEALTHMONIQUENELSONWINSGOLDSTEVIEAWARD--Soleo Health’s Monique Nelson Wins Gold Stevie® Award in the 2020 International Business Awards®

 

Decibel Therapeutics Appoints Dr. Elisabeth Leiderman as Chief Financial OfficerOpen in a New Window

BOSTON--(BUSINESS WIRE)--Decibel Therapeutics, a clinical-stage biotechnology company developing novel gene therapeutics for restoration of hearing loss and balance disorders, today announced the appointment of Elisabeth Leiderman, M.D., MBA, as Chief Financial Officer. “Elisabeth brings more than 15 years of business development, strategy and finance experience in the life sciences industry to our team at Decibel. She joins us at an important time as we build Decibel to advance our pipeline of

 

Talbots Third “The Art of the Scarf” Collection Honors National Breast Cancer Awareness MonthOpen in a New Window

--(BUSINESS WIRE)--Susan G. Komen: Who: Talbots has created its third “The Art of the Scarf” Collection with three internationally renowned female artists who each were commissioned to design a limited-edition one-of-a-kind silk scarf that tells a story. Full of colorful metaphors and meaning, the scarves evoke emotion with vibrant symbols of courage, strength and determination. The 41” scarves retail for $79.50. In the spirit of women helping women, Talbots will donate 10% of the net proceeds

 

Insights on the Global Ear Syringe Market 2020-2024 | COVID-19 Analysis, Drivers, Restraints, Opportunities and Threats | TechnavioOpen in a New Window

LONDON--(BUSINESS WIRE)-- #EarSyringeMarket--The Global Ear Syringe Market will grow by USD 9.23 mn during 2020-2024

 

Varex Announces Private Offering of $300 Million of Senior Secured NotesOpen in a New Window

SALT LAKE CITY--(BUSINESS WIRE)--Varex Imaging Corporation (Nasdaq: VREX) today announced it has commenced a private offering (the “Offering”), subject to market and other conditions, of $300 million aggregate principal amount of senior secured notes due 2027 (the “notes”). Varex intends to use the net proceeds from the sale of the notes to pay in full all amounts outstanding under its existing credit facility, which includes its term loan and revolving credit facility, and for general corporat

 

Frequency Therapeutics Completes Enrollment of FX-322 Phase 2a Study for Sensorineural Hearing LossOpen in a New Window

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the completion of enrollment of its Phase 2a study of FX-322 for sensorineural hearing loss (SNHL). The company anticipates obtaining full results for the study, in which 95 patients were enrolled, in the second quarter of 2021. “We are plea

 

TeleHealth Services Helps Yale New Haven Health System Connect Community to Share Support for Isolated PatientsOpen in a New Window

CARY, N.C.--(BUSINESS WIRE)-- #COVID19Response--Yale New Haven Health and TeleHealth Services developed a community program using cards of support and compassion presented on inpatient televisions.

 

Can-Fite to Participate in Two BioPharma Partnering ConferencesOpen in a New Window

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Participate in Two BioPharma Partnering Conferences

 

Medeor Therapeutics’ Transplant Immune Tolerance Therapy Receives Regenerative Medicine Advanced Therapy Designation from FDAOpen in a New Window

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Medeor announces that the FDA has granted an RMAT designation to MDR-101, designed to enable immune tolerance in kidney transplant patients

 

Omnicell Announces Proposed Private Placement of $500 Million of Convertible Senior NotesOpen in a New Window

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Announces Proposed Private Placement of $500 Million of Convertible Senior Notes

 

Seres Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics SummitOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the Jefferies Next Generation IBD Therapeutics Summit on Wednesday, September 23 at 8:00 a.m. E.T. A webcast of the presentation will be available under the “Investors and Media” section of Seres’ website and will be archived for 21 days. About Seres Therapeutics Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics platform company deve

 

Orthofix and Neo Medical Announce Partnership to Develop and Market Single-Use Spinal Solutions Focused on Improving Patient OutcomesOpen in a New Window

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. and Neo Medical SA announce partnership to develop and market single-use, sterile-packaged spinal solutions.

 

U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121)Open in a New Window

PRINCETON, N.J., & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BMY #BMS--FDA Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel....

 

Magellan Rx Management Earns NCQA Case Management AccreditationOpen in a New Window

PHOENIX--(BUSINESS WIRE)--Magellan Rx Management has earned NCQA Case Management Accreditation.

 

Anokion Announces Expansion of Exclusive Collaboration with Bristol Myers Squibb to Develop Novel Treatments for Autoimmune DiseasesOpen in a New Window

CAMBRIDGE, Mass. & LAUSANNE, Switzerland--(BUSINESS WIRE)--Anokion Announces Expansion of Exclusive Collaboration with Bristol Myers Squibb to Develop Novel Treatments for Autoimmune Diseases

 

Siolta Therapeutics Raises $30M Series B for the Prevention and Treatment of Allergic DiseasesOpen in a New Window

SAN CARLOS, Calif.--(BUSINESS WIRE)-- #livebiotherapeuticproducts--Siolta Therapeutics raises $30M series B to support clinical development of lead program for the prevention and treatment of allergic diseases.

 

Gyroscope Therapeutics Granted FDA Fast Track Designation for GT005, an Investigational Gene Therapy for Dry Age-Related Macular DegenerationOpen in a New Window

LONDON--(BUSINESS WIRE)-- #GeneTherapy--Gyroscope Therapeutics Granted FDA Fast Track Designation for GT005, an Investigational Gene Therapy for Dry Age-Related Macular Degeneration.

 

Medable Launches TeleConsent for Clinical Trials, Dramatically Improving Patient Access and ExperienceOpen in a New Window

PALO ALTO, Calif.--(BUSINESS WIRE)-- #biotech--Medable unveils TeleConsent software, making it easy for patients, sites and sponsors to share knowledge and streamline approvals for clinical trials.

 

Knight and TherapeuticsMD Announce Health Canada Approval of BIJUVA®Open in a New Window

MONTREAL & BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD and Knight announces approval of BIJUVA in Canada

 

Columbia Care Announces Illinois Expansion with Opening of Second Dispensary in Villa ParkOpen in a New Window

NEW YORK--(BUSINESS WIRE)--Columbia Care Announces Illinois Expansion with Opening of Second Dispensary in Villa Park

 

Bristol Myers Squibb Completes Acquisition of ForbiusOpen in a New Window

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Completes Acquisition of Forbius

 

Medis Selects Veeva CRM to Deliver Personalized Experiences to Healthcare ProfessionalsOpen in a New Window

PLEASANTON, Calif.--(BUSINESS WIRE)-- #cloud--Medis switched to multichannel Veeva CRM in 15 countries across Central and Eastern Europe to advance its commercial strategy.

 

Veeva Commercial Cloud Selected by Idorsia to Accelerate Digital Engagement GloballyOpen in a New Window

PLEASANTON, Calif.--(BUSINESS WIRE)-- #cloud--Idorsia selected Veeva Commercial Cloud to enable its digital field force in the U.S., Japan, and countries across Europe.

 

City of Hope Enters Licensing Agreement With Chimeric to Develop Its Pioneering Chlorotoxin CAR T Cell TherapyOpen in a New Window

DUARTE, Calif.--(BUSINESS WIRE)-- #CityofHope--City of Hope licensed intellectual property relating to its chlorotoxin chimeric antigen receptor T cell therapy to Chimeric Therapeutics Limited.

 

Ad Hoc Analysis of ARAMIS Showed a High Percentage (97.2%) of Men with Non-Metastatic Castration-Resistant Prostate Cancer Received Full, Planned Dosing of NUBEQA® (darolutamide)Open in a New Window

WHIPPANY, N.J.--(BUSINESS WIRE)--A new ad hoc analysis from the Phase III ARAMIS trial showed 97.2% of men with non-metastatic castration-resistant prostate cancer (nmCRPC) taking NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) received the full, planned dose of 600 mg twice daily compared to 98.4% who received ADT alone.1 The percent of planned dose was calculated as the actual dose received (sum of dose received over total time span) over the planned dose per protocol (sum of p

 

Recorded Conversations with Pebble Mine Executives Reveal Plans to Build Massive 180-Year Mine at the Headwaters of Bristol Bay in AlaskaOpen in a New Window

WASHINGTON--(BUSINESS WIRE)--Today the Washington DC-based non-profit the Environmental Investigation Agency (EIA) released recordings of conversations between EIA investigators and executives of Pebble Limited Partnership and Northern Dynasty Minerals (Pebble), the companies behind the contested Pebble Mine project in Alaska. The recordings, which EIA has dubbed “The Pebble Tapes,” reveal Pebble’s plans to build a large and long-lived mine at the headwaters of Bristol Bay in western Alaska. Th

 

The Medical Device Innovation Consortium (MDIC) Announces New Chair-Elect for Board of DirectorsOpen in a New Window

ARLINGTON, Va.--(BUSINESS WIRE)-- #MDIC--The Medical Device Innovation Consortium (MDIC) today announced that its board of directors has elected Jijo James, Chief Medical Officer of Johnson & Johnson Medical Devices Companies, as the new chair-elect of the MDIC board. James has been on the MDIC Board of Directors since 2017 and a member of the MDIC Executive Committee since 2018. He also chairs MDIC’s Clinical Science and Medical Officer forum, a group of senior scientific and medical executives fr

 

Pathline Labs Doubles Testing Capacity for COVID-19, Adds Major Clients Throughout U.S.Open in a New Window

RAMSEY, N.J.--(BUSINESS WIRE)--Pathline Labs has doubled its testing capacity for COVID-19 while maintaining a 24-36-hour turnaround time for processing.

 

Opdivo (nivolumab) Demonstrated Superior Disease-Free Survival in Patients with Resected Esophageal or Gastroesophageal Junction Cancer Compared to Placebo in the Adjuvant SettingOpen in a New Window

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Opdivo Demonstrated Superior Disease-Free Survival in Patients with Resected Esophageal or Gastroesophageal Junction Cancer Compared to Placebo.....

 

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Esophageal CancerOpen in a New Window

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Plus Chemotherapy Reduced Risk of Death by 27% Vs Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Esophageal Cancer

 

Opdivo (nivolumab) Plus Chemotherapy Demonstrated Significant Overall and Progression-Free Survival Benefits Versus Chemotherapy in First-Line Treatment of Gastric and Esophageal CancersOpen in a New Window

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Opdivo Plus Chemotherapy Demonstrated Significant Overall and Progression-Free Survival Benefits Versus Chemotherapy in First-Line Treatment....

 

BIOQUAL Announces Publication of an Investigational COVID-19 Vaccine Candidate That Prevents Severe Clinical Disease in AnimalsOpen in a New Window

ROCKVILLE, Md.--(BUSINESS WIRE)--A major objective of a COVID-19 vaccine is to prevent severe disease onset in SARS-CoV-2 infected people. Beth Israel Deaconess Medical Center (BIDMC) immunologist Dan H. Barouch, MD, PhD, and colleagues, including members of the staff at BIOQUAL, showed in recently published previous work that a candidate COVID-19 vaccine raised neutralizing antibodies that robustly protected non-human primates (NHPs) against SARS-CoV-2, the virus that causes COVID-19. In new r

 

FDA Report: DiaCarta COVID-19 Tests Rank Top 3 Among FDA SARS-CoV-2 Reference Panel TestsOpen in a New Window

RICHMOND, Calif.--(BUSINESS WIRE)--According to the recent FDA SARS-CoV-2 Reference Panel Comparative Data released on September 15, among all the FDA EUA tests with returned results, DiaCarta’s QuantiVirusTM SARS-CoV-2 Test and QuantiVirusTM SARS-CoV-2 Multiplex Test both rank within the top 3 for product sensitivity. With limit of detection (LoD) at 600 NDU/ml, these tests are 300 to 900-folds better than the least sensitive tests listed (180,000 NDU/ml VTM Swabs and 540,000 NDU/ml Dry Swabs)

 

Poxel Announces Participation at Upcoming Scientific and Investor ConferencesOpen in a New Window

LYON, France--(BUSINESS WIRE)--POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that members of the Poxel management and scientific team will participate at upcoming scientific and investor conferences. 56th European Association for the Study of Diabetes (EASD) Annual Meeting Date: September 21-25, 2020 (virtual co

 

Qihan Biotech Publishes First Clinical Xenotransplantation Prototype, ‘Pig 3.0’, in Nature Biomedical EngineeringOpen in a New Window

HANGZHOU, China--(BUSINESS WIRE)--Qihan Biotech published research reporting the successful production of its first clinical xenotransplantation prototype.

 

Governor Newsom Signs SB 1383 (Jackson) to Provide Job-Protected Paid Family Leave to More California WorkersOpen in a New Window

SACRAMENTO--(BUSINESS WIRE)--Governor Newsom Sign SB 1383 Paid Family Leave Expansion Bill

 

OnKure and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Combination of OKI-179 and BinimetinibOpen in a New Window

BOULDER, Colo.--(BUSINESS WIRE)--OnKure and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Combination of OKI-179 and Binimetinib.

 

Argonne National Laboratory and AT&T Extend Climate Resiliency Project NationwideOpen in a New Window

LEMONT, Ill.--(BUSINESS WIRE)--Argonne and AT&T announced they’re extending their changing climate analysis from America’s southeastern region to cover the entire contiguous U.S.

 

Trinity Life Sciences Breaks Down the Barriers for Biopharmaceutical Companies to Gain Actionable Real-World EvidenceOpen in a New Window

WALTHAM, Mass.--(BUSINESS WIRE)-- #EvidenceFirst--Trinity Life Sciences, a leader in global life sciences solutions, introduces Trinity EvidenceFirst™, a high-value subscription service that allows biopharmaceutical companies to take advantage of real-world insights like never before. EvidenceFirst allows organizations to benefit from big, robust data without dealing with the complexities, resource requirements, and costs associated with large data sets. With EvidenceFirst, biopharmaceutical companies can now u

 

Heart Valve Voice US to Train Patients As Research Advisors and AdvocatesOpen in a New Window

WASHINGTON--(BUSINESS WIRE)--Heart Valve Voice US—a patient-advocacy organization focused on improving the diagnosis, treatment, and management of heart valve disease—is pleased to introduce an intensive, virtual program to train patients and care partners to become research advisors and advocates. The program – Valuing Advocates’ Lives, Voices and Experience (VALVE) in Research – will be the basis for the creation of the heart valve disease research network (HVD Network). This training is bein

 

 Publix Pharmacy Opens in Halifax Health Medical CenterOpen in a New Window

LAKELAND, Fla.--(BUSINESS WIRE)--This morning, Publix Pharmacy opened a full-service pharmacy in Halifax Health Medical Center in Daytona Beach, Florida. The pharmacy will provide prescription and over-the-counter medications for patients, visitors and Halifax Health team members. “Publix Pharmacy is excited to begin serving the community at Halifax Health,” Publix Vice President of Pharmacy Dain Rusk said. “Halifax Health’s mission to deliver the best health care possible aligns with our cultu

 

About BioFlorida

BioFlorida is the voice of Florida's life sciences industry, representing 6,700 establishments and research organizations in the BioPharma, MedTech, HealthIT & BioAg that collectively employ nearly 94,000 Floridians.